XRx 225
Alternative Names: XRx-225Latest Information Update: 11 Apr 2022
At a glance
- Originator XORTX Pharma
- Developer XORTX Therapeutics
- Class Small molecules; Urologics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic nephropathies
Most Recent Events
- 07 Apr 2022 XORTX Pharma receives notification of intent to grant from the United States Patent Office for a patent covering xanthine oxidase inhibitors
- 19 Oct 2021 Preclinical trials in Diabetic nephropathies in Canada before October 2021 (unspecified route) (XORTX Therapeutics pipeline, October 2021)
- 01 Sep 2021 XORTX Pharma receives receipt of the patent grant “EPO National Stage of PCT International Application for Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office